Stem cell transplantation in patients with high-risk AML in first remission - A low relapse rate and acceptable transplant-related mortality after intensification of the conditioning regimen with Re-188 labelled anti-CD66 monoclonal antibody

被引：0
|
作者：
Bunjes, D
Buchmann, I
Wiesneth, M
Von Harsdorf, S
Duncker, C
Kotzerke, J
Seitz, U
Dohr, D
Stefanic, M
Glatting, G
Buck, A
Grimminger, W
Schlenk, R
Munzert, G
Dreger, P
Bergmann, L
Doehner, H
Reske, S
机构：
来源：
BONE MARROW TRANSPLANTATION | 2002年 / 29卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
O327
引用
收藏
页码：S56 / S56
页数：1
相关论文
共 30 条
  • [21] Allogeneic stem cell transplantation after reduced intensity conditioning (RIC) is effective for long-term disease control in high-risk AML patients in first complete remission
    Hemmati, Philipp G.
    Massenkeil, Gero
    Terwey, Theis H.
    Neuburger, Stefan
    Le Coutre, Philipp
    Vuong, Lam
    Dorken, Bernd
    Arnold, Renale
    BLOOD, 2007, 110 (11) : 887A - 887A
  • [22] Targeted radiotherapy in the conditioning prior to haematopoietic stem cell transplantation: Results of a phase I radiation dose escalation study using yttrium-90-labelled anti-CD66 monoclonal antibody demonstrating high BM uptake of radiation.
    Orchard, K
    Cooper, M
    Lewington, V
    Tristram, M
    Zivanovic, M
    Thom, J
    Quadri, S
    Richardson, D
    Causer, L
    Johnson, P
    BLOOD, 2005, 106 (11) : 618A - 618A
  • [23] Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients:: Comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection
    Canals, C
    Martino, R
    Sureda, A
    Altés, A
    Briones, J
    Subirá, M
    Ancín, I
    Martín-Henao, G
    Brunet, S
    Sierra, J
    EXPERIMENTAL HEMATOLOGY, 2003, 31 (11) : 1039 - 1043
  • [24] Low relapse without excessive transplant-related mortality following allogeneic stem cell transplantation in patients with high-risk secondary acute myeloblastic leukaemia and myelodysplastic syndromes: long-term outcomes in a single-centre experience
    Castagna, L.
    Furst, S.
    Faucher, C.
    Charbonnier, A.
    Vey, N.
    Blaise, D.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S92 - S93
  • [25] High Response RATE and NO Treatment Related Mortality After Brentuximab Vedotin Salvage Therapy Followed by Reduced Intensity Conditioning Regimen Allogeneic STEM CELL Transplantation (RIC-ALLO) in Patients with CD 30+Lymphomas
    Furst, Sabine
    Bouabdallah, Reda
    Coso, Diane
    Crocchiolo, Roberto
    El-Cheikh, Jean
    Faucher, Catherine
    Granata, Angela
    Oudin, Claire
    Venton, Geoffroy
    Stoppa, Anne Marie
    Lemarie, Claude
    Chabannon, Christian
    Blaise, Didier
    BLOOD, 2012, 120 (21)
  • [26] High response rate and no treatment-related mortality after brentuximab vedotin salvage therapy followed by reduced-intensity conditioning regimen allogeneic stem cell transplantation (RIC-ALLO) in patients with CD 30+lymphomas
    Fuerst, S.
    Bouabdallah, R.
    Coso, D.
    Crocchiolo, R.
    El Cheikh, J.
    Faucher, C.
    Castagna, L.
    Granata, A.
    Oudin, C.
    Venton, G.
    Stoppa, A.
    Lemarie, C.
    Chabnnon, C.
    Blaise, D.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S233 - S233
  • [27] Lower Absolute Lymphocyte Count Before Conditioning Predicts High Relapse Risk in Patients After Haploidentical Peripheral Blood Stem Cell Transplantation With Low Dose Anti-Thymocyte Globulin/Post-Transplant Cyclophosphamide for GvHD Prophylaxis
    Zhou, Xiao
    Cai, Yu
    Yang, Jun
    Tong, Yin
    Qiu, Huiying
    Huang, Chongmei
    Zhou, Kun
    Xu, Xiaowei
    Niu, Jiahua
    Xia, Xinxin
    Zhang, Ying
    Shen, Chang
    Wei, Yu
    Song, Xianmin
    Wan, Liping
    CELL TRANSPLANTATION, 2022, 31
  • [28] Influence of pre-transplant immunosuppression and post-transplant immune reconstitution on relapse rate and event-free survival after allogeneic blood stem cell transplantation (alloBSCT) following FLAMSA-Melphalan conditioning in patients with high-risk myeloid leukemia (HR-ML)
    Groten, A.
    Schroeder, T.
    Dienst, A.
    Nachtkamp, K.
    Rachlis, E.
    Germing, U.
    Haas, R.
    Kondakci, M.
    Kobbe, G.
    ONKOLOGIE, 2013, 36 : 120 - 120
  • [29] Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome
    Pagel, John M.
    Gooley, Theodore A.
    Rajendran, Joseph
    Fisher, Darrell R.
    Wilson, Wendy A.
    Sandmaier, Brenda M.
    Matthews, Dana C.
    Deeg, H. Joachim
    Gopal, Ajay K.
    Martin, Paul J.
    Storb, Rainer F.
    Press, Oliver W.
    Appelbaum, Frederick R.
    BLOOD, 2009, 114 (27) : 5444 - 5453
  • [30] A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    Mawad, Raya
    Gooley, Ted A.
    Rajendran, Joseph G.
    Fisher, Darrell R.
    Gopal, Ajay K.
    Deeg, H. Joachim
    Shields, Andrew
    Green, Damian J.
    Maloney, David G.
    Sandmaier, Brenda M.
    Storb, Rainer
    Appelbaum, Frederick R.
    Press, Oliver W.
    Pagel, John M.
    BLOOD, 2012, 120 (21)
123